Pfizer is axing its neurosciences division, laying off 300 and discarding new drugs
Pfizer is starting out 2018 by ripping up its early-, mid-stage and preclinical R&D operations focused on neurosciences and laying off hundreds of workers engaged in the development work.
In a statement, Pfizer $PFE says it is is axing about 300 workers in Connecticut and Massachusetts — about 100 each in Andover, Groton and Cambridge, where it’s been concentrating its R&D efforts — and discarding a slate of Phase I/II and preclinical studies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.